TVM Capital

TVM Capital Life Science is a prominent global venture and growth capital firm with a specialized focus on the biopharmaceutical, medical technology, and digital health sectors. Headquartered in Munich, Germany, with additional offices in Boston, USA, and Montreal, Canada, the firm has established itself as a key player in financing innovative life science companies from early-stage development through to growth. Their investment philosophy is deeply rooted in identifying and supporting companies with high-potential drug candidates and medical devices that address significant unmet medical needs.

A distinctive aspect of TVM Capital Life Science's strategy is its pioneering "asset-centric" or "project-specific financing" model. This approach often involves creating special purpose vehicles (SPVs) around a single promising drug candidate or medical technology, allowing for focused investment and de-risking of development. This model provides a flexible financing solution for biotech and medtech innovators, enabling them to advance specific assets through critical development milestones. The firm typically targets initial investments ranging from $5 million to $20 million per company, with the capacity for substantial follow-on funding as projects progress, aiming to build a concentrated portfolio of 10 to 15 companies per fund.

TVM Capital Life Science has demonstrated consistent fundraising success, underscoring its strong investor confidence and commitment to the life sciences. Their most recent fund, TVM Life Science Innovation IV (TVM LSI IV), closed in 2023 with €180 million, following previous successful funds like TVM LSI III (€150 million in 2020) and TVM LSI II (€118 million in 2017). This significant capital base allows them to provide robust financial backing and strategic guidance to their portfolio companies, fostering the development of groundbreaking therapies and technologies. Their long-standing presence and deep industry expertise position TVM Capital Life Science as a crucial partner for entrepreneurs in the global life science ecosystem.